This document summarizes a clinical trial evaluating a novel microcrystalline paclitaxel coated balloon (mcPCB, PAX) for the treatment of femoropopliteal restenosis. The trial aims to evaluate the safety and efficacy of the mcPCB compared to uncoated balloons or standard care. It will be a multicenter, randomized controlled trial enrolling patients with claudication due to restenosis within a previously revascularized femoropopliteal segment. Previous studies on paclitaxel coated balloons showed reductions in restenosis compared to uncoated balloons. This novel mcPCB technology aims to provide a more consistent, uniform drug coating distribution compared to earlier generation